• 1. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 2. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines 6-aminopurines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives 6-aminopurines

Introduction to 3-Ethyl-adenine (CAS No. 43003-87-8)

3-Ethyl-adenine, with the chemical formula C?H??N? and CAS number 43003-87-8, is a nucleoside analog that has garnered significant attention in the field of pharmaceutical and biochemical research. This compound is structurally related to adenosine, featuring an ethyl group at the 3-position of the purine ring. Its unique molecular architecture makes it a valuable tool in studying nucleic acid interactions and developing novel therapeutic agents.

The synthesis of 3-Ethyl-adenine involves multi-step organic reactions, typically starting from purine derivatives and employing protective group strategies to selectively introduce the ethyl moiety. Advanced synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions, have been employed to enhance yield and purity, making it more accessible for large-scale applications.

One of the most compelling aspects of 3-Ethyl-adenine is its potential in medicinal chemistry. Researchers have explored its derivatives as antimicrobial and anticancer agents. For instance, modifications at the 6-position or 8-position of the purine ring have led to compounds with enhanced binding affinity to DNA and RNA. These modifications are critical for developing drugs that can interfere with pathogenic processes without affecting host cells.

Recent studies have highlighted the role of 3-Ethyl-adenine in modulating enzyme activity, particularly adenosine deaminase (ADA). ADA is an enzyme that degrades adenosine, a neurotransmitter involved in various physiological processes. Inhibitors of ADA have been investigated for their potential in treating neurological disorders such as Parkinson's disease and multiple sclerosis. The structural similarity between 3-Ethyl-adenine and adenosine allows it to serve as a scaffold for designing ADA inhibitors with improved pharmacokinetic properties.

The pharmacological profile of 3-Ethyl-adenine has also been studied in the context of its interaction with nucleic acid-binding proteins. For example, its ability to mimic natural nucleosides has been exploited in antisense therapy, where it can hybridize with specific mRNA sequences to block protein translation. This approach has shown promise in treating genetic disorders by selectively silencing harmful genes.

In addition to its therapeutic applications, 3-Ethyl-adenine has been utilized as a research tool in understanding the mechanisms of nucleic acid replication and transcription. Its incorporation into DNA or RNA can provide insights into how these molecules function at a molecular level. Such studies are crucial for developing targeted therapies against viruses and bacteria that rely on nucleic acid replication for their survival.

The chemical stability of 3-Ethyl-adenine under various conditions has been thoroughly investigated. Researchers have found that it exhibits good stability in aqueous solutions at physiological pH, making it suitable for biological assays and drug formulations. However, its stability can be affected by extreme temperatures or acidic environments, necessitating careful handling during storage and administration.

Industrial-scale production of 3-Ethyl-adenine has been optimized to meet the demands of pharmaceutical companies. Continuous flow chemistry has emerged as a promising technique for synthesizing this compound efficiently while minimizing waste. Such advancements not only reduce production costs but also align with sustainable chemistry principles by promoting greener synthetic routes.

The regulatory landscape for 3-Ethyl-adenine as a pharmaceutical compound is evolving. Regulatory agencies require comprehensive toxicological data before approving new drugs based on nucleoside analogs like this one. Preclinical studies involving animal models have provided valuable insights into its safety profile, including potential side effects and interactions with other drugs.

Future research directions for 3-Ethyl-adenine include exploring its role in gene editing technologies such as CRISPR-Cas systems. By modifying its structure to enhance compatibility with guide RNAs, it could be used to improve the precision and efficiency of gene editing tools. This would open up new avenues for treating genetic diseases by directly targeting faulty genes.

The interdisciplinary nature of research involving 3-Ethyl-adenine underscores its importance in advancing both chemistry and medicine. Collaborations between synthetic chemists, biochemists, and clinicians are essential for translating laboratory discoveries into tangible therapeutic benefits. Such interdisciplinary efforts are key to addressing complex diseases that require innovative solutions.

• 707-99-3(2-(6-Aminopurin-9-yl)ethanol)
• 24309-36-2(7-Ethyl Adenine)
• 2715-68-6(9-Ethyl Adenine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)